In contrast, other investigators have reported a significant adverse effect on overall survival in patients with AML [51], and a recent CALGB report of 427 patients with cytogenetically normal AML found that TET2 mutations were associated with a lower rate of CR and shorter disease-free and overall survival, with outcomes particularly worse for patients with favorable risk (CEPBA and NPM1 mutant) disease [62]. This evidence concerns the gene TET2 and acute myeloid leukemia.